MGRX | Mangoceuticals, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	2.2000 - 2.3700
52 Week Range	2.1000 - 16.80
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	54,380
Average Volume	358,047
Shares Outstanding	1,993,720
Market Cap	4,725,116
Sector	Healthcare
Industry	Medical - Healthcare Information Services
IPO Date	2023-03-21

Valuation
Profitability
Growth
Health
P/E Ratio	-0.37
Forward P/E Ratio	N/A
EPS	-6.45
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	3
Country	USA
Website	MGRX

Mangoceuticals, Inc. focuses on develops, markets, and sells various men's wellness products and services through a telemedicine platform. It offers erectile dysfunction products under the Mango brand name. The company sells its products through online website mangorx.com. Mangoceuticals, Inc. was incorporated in 2021 and is headquartered in Dallas, Texas. Mangoceuticals, Inc. operates as a subsidiary of Cohen Enterprises, Inc.

MGRX's peers: BEAT, HCTI, ZCMD, NUTX, ACON, EUDA, FOXO, ETAO, SNCE, BFRG, UTRS, ACONW, AKLI, AUGX

*Chart delayed

Analyzing fundamentals for MGRX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see MGRX Fundamentals page.

Watching at MGRX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on MGRX Technicals page.